Resperate© (Intercure Ltd) (not routinely commissioned)

For the treatment of

Hypertension

Commissioning position

This intervention is not commissioned and therefore should not be routinely offered to patients. Application for funding approval can be made, using the IFR process, by the clinician recommending the intervention, if their assessment is that there are exceptional reasons why their patient could benefit from it.

Summary of rationale

Relaxation therapies, such as slow breathing exercises have been studied as possible non-pharmacological interventions to lower blood pressure and consequently contribute to management of Hypertension. Device-guided breathing is one approach to slow breathing ,and the Resperate® device has received US FDA and UK NHS approval as a prescribable device. However, the evidence of clinical effectiveness of this device is inconclusive and insufficient to recommend its use as a treatment for Hypertension. It is not recommended within current NICE guidance on management of Hypertension and the British Hypertension Society issued a statement, following its listing in the NHS Drug Tariff, stating that there was not sufficient evidence for this equipment to be recommended.